ALNYLAM PHARMACEUTICALS SHARES DOWN 12.9% PREMARKET AFTER CO POSTS DETAILED RESULTS FROM LATE-STAGE STUDY OF HEART DRUG

Reuters · 08/30 10:37
ALNYLAM PHARMACEUTICALS SHARES DOWN 12.9% PREMARKET AFTER CO POSTS DETAILED RESULTS FROM LATE-STAGE STUDY OF HEART DRUG